These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25993188)

  • 1. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
    Weinstock M; McDermott DF
    Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
    Thomas JS; Kabbinavar F
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
    Gill D; Hahn AW; Sonpavde G; Agarwal N
    Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy for Renal Cell Carcinoma].
    Büchler T
    Klin Onkol; 2015; 28 Suppl 4():4S64-8. PubMed ID: 26647891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New immunotherapy in the treatment of advanced renal cancer.
    Muto A; Gridelli C
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):233-237. PubMed ID: 31751164
    [No Abstract]   [Full Text] [Related]  

  • 9. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
    Schmidinger M
    Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immunotherapy in kidney cancer.
    Nazzani S; Bazinet A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunotherapy in metastatic renal cell carcinoma.
    Cho YH; Kim MS; Chung HS; Hwang EC
    Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immunotherapies for renal cell carcinoma.
    Escudier B
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii35-40. PubMed ID: 22918926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
    Pal SK; Hu A; Chang M; Figlin RA
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
    Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
    Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.